Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGF shRNA
- Development stage
- Preclinical
- Lead developer
- Inomagen Therapeutics
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intraganglionic, Intra-cardiac, Intratracheal, Intraparenchymal, Intracerebroventricular, Intrathecal, In Vitro Transfection
01
Overview
NGF shRNA is a preclinical gene therapy program being developed by Inomagen Therapeutics that utilizes short hairpin RNA (shRNA) technology to knock down the expression of nerve growth factor (NGF). The therapy is designed to target the autonomic nervous system to prevent or treat neural remodeling, which is a key factor in the development of cardiac arrhythmias like atrial fibrillation. The program leverages Inomagen's proprietary TRAVGE™ platform, a non-viral, electroporation-based delivery system intended to provide localized and efficient gene transfer to the heart or other target tissues. While currently in the research stage, it represents a strategic expansion of Inomagen's pipeline beyond its lead NOX2 shRNA candidate.
- Other names
- nerve growth factor short hairpin RNANGF-shRNA gene therapy
02
Targets
NGF (Nerve growth factor)
Beyond the preview
Go deeper on NGF shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGF shRNA.